IGM Biosciences is a clinical-stage biotechnology company engaging in the development of Immunoglobulin M (IgM) antibodies for the treatment of cancer, autoimmune and inflammatory diseases and infectious diseases. Co.'s product candidates include: IGM-8444, which is an IgM antibody targeting Death Receptor 5 proteins for the treatment of patients with solid and hematologic malignancies; Imvotamab, which is a bispecific T cell engaging IgM antibody targeting CD20 and CD3 proteins; IGM-7354, which is an IgM antibody targeting the delivery of interleukin-15 to the area of PD-L1 expressing cells; and IGM-2644, which is a bispecific T cell engaging IgM antibody targeting CD38 and CD3 proteins. The IGMS average annual return since 2019 is shown above.
The Average Annual Return on the IGMS average annual return since 2019 page and across the coverage universe of our site,
is a measure of the annualized return over the past ten years (or specified start date) for a given investment
(up to the end of prior trading session recorded). Arguably, choosing ten years for a measurement
period is on the one hand completely arbitrary, but on the other hand provides a sufficiently long window
to capture long-term trends.
Thus, researching Average Annual Returns is good practice for investors — whether IGMS average annual return since 2019 or other benchmarks/peers
— and when doing so it is also important to factor in dividends, because a financial instrument's annualized return is
more than just the change in price if that instrument pays a dividend or coupon. Our website aims to empower investors
by performing the IGMS average annual return calculation with any dividends reinvested as applicable (on ex-dates).
|